Adjuvant Primary News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Adjuvant Primary. Real-time updates on events, politics, business and more.

IDEAYA BIOSCIENCES, INC. : Other Events (form 8-K)

April 24, 2023

Item 8.01 Other Events Clinical Updates On April 23, 2023, IDEAYA Biosciences, Inc. announced interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib synthetic... | June 18, 2023

New South Wales United States While The Company Biosciences Inc Company Annual Report On Form Company Phase

Source: marketscreener.com

IDEAYA Biosciences : Clinical Updates - Form 8-K

April 24, 2023

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | June 18, 2023

United States South San Francisco New South Wales Yujiro Hata Vincent Hospital Sydney Biosciences Inc

Source: marketscreener.com

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma

April 23, 2023

Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational... | April 23, 2023

South Australia New South Wales Neoadjuvant Po Meredith Mckean Anthony Joshua Mark Shackleton

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Adjuvant Primary News Today

IDEAYA BIOSCIENCES, INC. : Other Events (form 8-K)

IDEAYA Biosciences : Clinical Updates - Form 8-K

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma

Explore More Categories